Aims/hypothesis By combining multiple genome-wide association (GWA) studies and comprehensive replication efforts, 12 novel type 2 diabetes associated loci have recently been discovered. Here we evaluate the effect of lead variants of these loci on estimates of insulin release and insulin resistance derived from an oral glucose tolerance test. Methods We examined 12 lead variants in or near HMGA2, CENTD2 (also known as ARAP1), KLF14, PRC1, TP53INP1, ZBED3, ZFAND6, CHCHD9, DUSP9, KCNQ1, BCL11A and HNF1A in 5,722 middle-aged people from the population-based Inter99 sample.
Results Carriers of the major diabetogenic allele of rs1552224 in CENTD2 had increased 30-min plasma glucose values (2.0%, p=2×10 −5 ) as well as 4.2% reduced insulin release 30 min after an oral glucose load (p=0.001). Risk allele carriers also had decreased BIGTT-acute insulin release (AIR), which is a surrogate measure of insulin release where sex, BMI, plasma glucose and serum insulin are integrated (5.3%, p=8×10 −7 ). In addition, a decreased corrected insulin response (CIR; 9.9%, p = 3 × 10 −8 )
was observed. For rs5945326 near DUSP9 on the X-chromosome we stratified according to sex. Male carriers of the risk allele showed nominally decreased BIGTT-AIR (2.6%, p=0.01). No associations with intermediate meta-
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Introduction
Since 2007, the list of common validated type 2 diabetes genes has grown substantially due to the results of genomewide association (GWA) studies. The Diabetes Genetics Replication and Meta-analysis (DIAGRAM) consortium have, in 2008 and 2010, reported results from large metaanalyses [1, 2] . In the latest extended analysis (referred to as DIAGRAM+) 12 novel type 2 diabetes genes were discovered [2] ; however, these novel loci affect disease risk modestly with odds ratios between 1.06 and 1.14 [2] . Only rs5945326, near DUSP9 on the X chromosome, seems to have an effect size comparable to some of the loci discovered in the earlier studies (combined odds ratio 1.27). Due to the sparse knowledge concerning the diabetescausing mechanisms of the newly identified variants, the aim was to explore the intermediate phenotypes that may explain the observed disease association. Hence, we characterised the influence of these variants on surrogate measures of beta cell function and insulin sensitivity derived from an OGTT in a random population of middle-aged Danes.
Methods
Study population All analyses were conducted in nondiabetic people from the Inter99 Study sample [3] . Clinical characteristics and a description of the Inter99 Study population are shown in Electronic supplementary material (ESM) Study population and ESM Table 1 . Informed written consent was obtained prior to investigation. The study was conducted in accordance with the principles of the Helsinki Declaration II.
Derived estimates of insulin release and insulin sensitivity from an OGTT The insulinogenic index, BIGTT-acute insulin response (AIR) and the corrected insulin response (CIR) were reported as indices of oral glucose-stimulated insulin release. The insulinogenic index was calculated as follows: serum insulin 30min À serum insulin 0min pmol=l ½ ð Þ = plasma glucose 30min mmol=l ½ . CIR was calculated as:
89Þ [4] . The BIGTT indices integrate information on sex and BMI, combined with plasma glucose and serum insulin, during an OGTT and were calculated as reported [5] . The surrogate measures of insulin sensitivity, BIGTT sensitivity index (S I ) and the homeostasis model assessment of insulin resistance (HOMA-IR) ([plasma glucose 0 min (mmol/l)× serum insulin 0 min (pmol/l)]/22.5), respectively, were calculated as reported [5, 6] . Two different disposition indices (DIs) were calculated based on the OGTT; for DI 1 we multiplied BIGTT-AIR with BIGTT-S I and for DI 2 we divided CIR by HOMA-IR.
Genotyping All variants were genotyped by KASPar SNP Genotyping (KBiosciences, Hoddesdon, UK). All success rates were above 95% and all error rates below 0.85% in 591 duplicates. All variants were in Hardy-Weinberg equilibrium in the Inter99 Study (p>0.005).
Statistical analysis The effects of 12 lead variants on quantitative traits related to type 2 diabetes were analysed using linear regression models under an additive model. Values for plasma glucose, serum insulin and derived indices (except BIGTT-S I ), were logarithmically (log e ) transformed before analyses. To investigate the interaction between sex and DUSP9 rs5945326 we included an interaction term (sex×genotype) in the linear model in addition to the main effects. Correction for multiple testing was performed by Bonferroni (correcting for 12 SNPs), and a p value below 0.004 was considered significant. A p value between 0.05 and 0.004 was considered nominally significant. All statistical analyses were performed with the statistical programming language R (version 2.10.1) (www. r-project.org).
Statistical power calculations Statistical power for quantitative traits was estimated using simulations. An additive genetic model was used for both the simulation of the data and for testing the data using a linear model. We used the empirical variance of the observed traits (insulinogenic index and HOMA-IR) to simulate phenotypes from the normal distribution so that variance across genotypes is drawn from the estimated variance.
Since no prior studies have assessed the effect size of the OGTT-derived estimate of insulinogenic index and HOMA-IR on the 12 SNPs, we included the calculated effect sizes from the Inter99 Study population. Given a study sample of 5,000, CENTD2 (also known as ARAP1) rs1552224 is the only novel SNP with statistical power above 80% to find the observed effect size for the insulinogenic index (ESM Table 2 ).
In addition, a complementary method to calculate statistical power was applied. We used the allele frequencies of the 12 novel type 2 diabetes genes and a sample size of 5,722 individuals to estimate the effect size for each allele for which we had 80% statistical power to detect an association in the given quantitative trait. We carried out 5,000 simulations and applied a significance threshold of 0.004. We had 80% statistical power to detect an allelic difference of 5.4-9.7% in CIR, 2.8-5.3% in BIGTT-AIR and 0.27-0.51 absolute difference in BIGTT-S I , respectively.
Results
In case-control settings, seven of the 12 variants that were reported to reach genome-wide significance in the DIA-GRAM+ meta-analysis were nominally associated with type 2 diabetes in the Danish population (p<0.05). These results are part of the DIAGRAM+ meta-analysis [2] , but are shown in the ESM for comparison (ESM Table 3 ).
In the population-based Inter99 Study sample of 5,722 individuals, carriers of the major diabetogenic allele of rs1552224 near CENTD2 had a 4.2% lower 30-min serum insulin release (95% CI 1.7-6.7, p=0.001) per risk allele Data are means±SD, median (interquartile range), or per-risk-allele effect size (95% CI)
Units of effect sizes are kg/m
(BMI), no units (BIGTT-S I ) or% (all other traits)
BIGTT indices integrate information on sex and BMI combined with plasma glucose and serum insulin during an OGTT to provide indices for AIR and S I and were calculated as reported [5] Values of serum insulin and plasma glucose, as well as derived indices of insulinogenic index, HOMA-IR, BIGTT-AIR, CIR, DI 1 and DI 2 were logarithmically transformed before analysis following an OGTT ( ]; Table 1 ). The results remained largely unchanged when we added HOMA-IR to the model as a covariate in the analyses of indices of insulin release (Table 1) .
Of the remaining 11 SNPs, 10 demonstrated no convincing association with any quantitative traits related to insulin release or insulin sensitivity (ESM Table 4 ). DUSP9 rs5945326 was analysed further because of its location on the X-chromosome. When we stratified according to sex, we found nominal associations with indices of insulin release in men (n=2,694). Male risk allele carriers had nominally lower BIGTT-AIR, (2.6% [95% CI 0.6-4.5, p=0.01]) and, when adding HOMA-IR as a covariate, the association with BIGTT-AIR (2.8% [95% CI 1.0-4.6, p =0.002]) was strengthened. A tendency towards a decrease in CIR and the two disposition indices was also observed (p<0.06; ESM Table 5 ). We did not find associations with any quantitative trait in women (ESM Table 5 ). We also examined for interaction between sex and DUSP9 genotype, and found indications of different association patterns for traits related to beta cell dysfunction, indicating stronger effects of the genotype in men (ESM Table 5 ).
Discussion
We report the association testing of 12 recently discovered type 2 diabetes risk variants with intermediary diabetesrelated phenotypes in middle-aged individuals. Our results suggest an impairment of pancreatic beta cell function for diabetes risk alleles of the lead variant (rs1552224) at CENTD2. In addition, we provide suggestive evidence that rs5945326, near DUSP9 on the X-chromosome, is mediating its effect through reduced beta cell function in men. As for the remaining ten type 2 diabetes susceptibility loci, no convincing associations were established to the surrogate measurements of beta cell function or insulin sensitivity in this Danish population-based study.
The DIAGRAM+ consortium provided a new understanding of the potential physiological roles of the 12 new type 2 diabetes susceptibility loci by running quantitative trait studies of fasting plasma glucose and fasting serum insulin levels [2] . The majority of SNPs showed higher fasting glucose for type 2 diabetes risk alleles. In addition, the lead variant of KLF14 showed an increased fasting serum insulin level, suggesting a primary insulin desensitising effect, whereas the diabetes associated variants at CENTD2 associated with reduced fasting serum insulin concentrations indicating reduced beta cell function. However, in the DIAGRAM+ Study, only two of these 12 new loci showed significant association to surrogate measures of insulin release and insulin sensitivity, as the risk allele at CENTD2 associated with a lower HOMA-B, and the risk allele at KLF14 associated with a higher HOMA-IR [2] . Although we recognise HOMA-B as a widely used measure of beta cell capacity, it is important to emphasise that this surrogate measure reflects insulin release under nonstimulated conditions [7] , whereas, in the present report, we applied OGTT-derived surrogate measures to estimate the glucose-stimulated insulin response; a method which has been shown to be superior to the HOMA-B model in estimating the crucial first phase insulin release [7] . For the CENTD2 locus, DIAGRAM+ and the present study both report that CENTD2 mediates its effect through a reduced beta cell function, whereas we failed to reproduce the effect of KLF14 on estimates of insulin sensitivity. In the Inter99 Study sample we only have a statistical power of 16% to find a similar effect size of HOMA-IR for KLF14 as reported in the DIAGRAM+ paper [2] , which might explain the missing associations in the present study.
Our studies of middle-aged men from the Inter99 cohort indicate that rs5945326, near DUSP9, may increase risk of type 2 diabetes through an impairment of glucosestimulated insulin release. Yet, the evidence for these findings is sparse. In DIAGRAM+, the X-chromosome was only investigated with regard to fasting glucose and insulin in a subset of the full study population, and no associations with these traits were reported, nor was any sex specific association demonstrated. A future metaanalysis of association signals, GWAS, and additional fine mapping of the DUSP9 locus with emphasis on this possible sex specific association will be of interest.
In contrast to CENTD2, where there is no reported biological data to support an effect on beta cell function, DUSP9 (which codes for mitogen-activated dual specificity protein kinase phosphastase-4) has been identified as a gene involved in insulin signalling and in the pathogenesis of insulin resistance [8] [9] [10] .
For the remaining ten loci, with odds ratios of 1.06-1.14, we found no convincing association to any quantitative traits related to type 2 diabetes in the Inter99 Study. By combining data in large meta-analyses, as in the DIA-GRAM consortium, these new, interesting type 2 diabetes susceptibility loci were discovered. However, investigations of intermediary phenotypes with low effect sizes require large numbers of individuals. To illustrate this we performed statistical power analyses in different scenarios (see ESM Table 2 ), demonstrating the need for combining efforts in further meta-analyses when searching for the diabetes intermediary phenotype.
In conclusion, we report data that support and extend the findings of an impaired beta cell function in carriers of the major diabetogenic allele of CENTD2 rs1552224. The situation regarding the remaining 11 loci calls for further investigation in large-scale association studies in wellcharacterised study populations.
